Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use.
about
The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia.Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort study.Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort.Early-onset baldness and the risk of aggressive prostate cancer: findings from a case-control study.Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.Possible association between androgenic alopecia and risk of prostate cancer and testicular germ cell tumor: a systematic review and meta-analysis.Nutraceuticals in prostate cancer therapeutic strategies and their neo-adjuvant use in diverse populationsMale pattern baldness and incidence of prostate cancer: A systematic review and meta-analysis
P2860
Q38798979-F7651B04-9820-47CF-BE6C-0C39EB3A4C5EQ40041065-B5618705-43D6-481C-8FCE-FDD4CC24D597Q40382361-47BD354B-C352-4C8E-9C9E-5E4E1C1B0082Q47570403-18B99DF1-FD1E-475E-9BE6-99C94F3DED3DQ50012629-36649FAA-7872-44B8-9601-E300FE300205Q51244733-E01CF2E5-E763-4702-8890-700D296955C6Q55154528-401D18EA-F81C-40A4-ADF5-5C3F8AA69845Q57109257-76413B93-FBA8-4F93-85C6-7B14D30E1EB9Q57110520-82CBBEFD-D877-4179-8228-164CDC4C6FC0
P2860
Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Postscreening follow-up of the ...... al anti-inflammatory drug use.
@en
type
label
Postscreening follow-up of the ...... al anti-inflammatory drug use.
@en
prefLabel
Postscreening follow-up of the ...... al anti-inflammatory drug use.
@en
P2093
P2860
P1476
Postscreening follow-up of the ...... al anti-inflammatory drug use.
@en
P2093
Liisa Määttänen
Sami Sarre
Teemu J Murtola
Teuvo L J Tammela
P2860
P304
P356
10.3109/21681805.2016.1145734
P577
2016-02-29T00:00:00Z